Patient-derived organoids: an emerging platform to de-risk immunotherapy development
On demand

Patient-derived organoids: an emerging platform to de-risk immunotherapy development

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Patient-derived organoids: an emerging platform to de-risk immunotherapy development

Recent advances in cancer immunotherapy have had a positive impact on the life expectancy of patients with liquid cancers. With new treatment strategies and druggable targets being identified at an increasing pace, the number of patients eligible for cancer immunotherapy is expected to expand rapidly. However, promising therapeutic developments face hurdles in translating preclinical findings into therapy since conventional 2D cancer models hold low clinical predictive value.

Patient-derived organoids (PDOs) generated from healthy and malignant tissues recapitulate complex characteristics of the original parental tissue, including molecular heterogeneity, morphological and functional traits. Importantly, they preserve tumour-specific antigens that are conventionally lost in standard in vitro models, therefore representing an excellent system to investigate target engagement, mechanisms of action, and to stratify a patient population based on tumour molecular features.

This webinar will spotlight the development of autologous PDO and immune cell biobanks relevant for testing immune-oncology agents and co-culture assays, to evaluate different immuno-oncology products such as CAR-T cells, T cell engagers, and checkpoint inhibitors.

  • Learn about the benefits of patient-derived organoids compared to standard in vitro models
  • Find out about established co-culture systems and under development projects
  • Learn how PDOs are currently being used to evaluate the efficacy of CAR-T cells, T cell engagers and checkpoint inhibitors
  • Understand PDO applications across the drug development pipeline, from target engagement/validation to mechanism of action and lead selection studies
  • Discover how organoids are helping to replace, refine, and reduce animal use in immunotherapy development
Sylvia F Boj
Sylvia F Boj
Chief Scientific Officer, HUB Organoids
Sylvia received her PhD in 2006 at the University of Barcelona, Spain for her work at the Hospital Clinic in the laboratory of Prof. Jorge Ferrer, where she conducted functional genetic analysis to understand the transcriptional role of MODY genes in pancreatic beta cells. With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 in regulating metabolism. Then, she established human pancreas organoids from tumor resections in collaboration with the Surgery and Pathology departments from the UMC and the laboratory of Prof. D.A. Tuveson.In 2014, she joined HUB as one of the founding scientists and worked as a Group Leader for the cystic fibrosis and pancreatic cancer organoid programs. In 2016, she was appointed Scientific Director at HUB and in her new role she was responsible for leading both the contract service and research programs. Under Sylvia´s leadership the Organoid Technology evolved from a highly innovative basic research tool to a industry leading drug development platform. Since 2020 she holds the position of Chief Scientific Officer.
Andrea Bisso
Andrea Bisso
Associate Director of Pharmacology & Pre-Clinical Development, Gadeta BV